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ABSTRACT
Introduction Approximately one million undiagnosed 
persons living with HIV in Southern and Eastern Africa need 
to test for HIV. Novel approaches are necessary to identify 
HIV testing options that match the heterogeneous testing 
preferences of high- risk populations. This pragmatic 
randomised controlled trial (PRCT) will evaluate the 
efficacy of a preference- informed, heterogeneity- focused 
HIV counselling and testing (HCT) offer, for improving rates 
of HIV testing in two high- risk populations.
Methods and analysis The study will be conducted in 
Moshi, Tanzania. The PRCT will randomise 600 female 
barworkers and 600 male Kilimanjaro mountain porters 
across three study arms. All participants will receive an HIV 
testing offer comprised of four preference- informed testing 
options, including one ‘common’ option—comprising 
features that are commonly available in the area and, on 
average, most preferred among study participants—and 
three options that are specific to the study arm. Options 
will be identified using mixed logit and latent class 
analyses of data from a discrete choice experiment (DCE). 
Participants in Arm 1 will be offered the common option 
and three ‘targeted’ options that are predicted to be more 
preferred than the common option and combine features 
widely available in the study area. Participants in Arm 2 
will be offered the common option and three ‘enhanced’ 
options, which also include HCT features that are not yet 
widely available in the study area. Participants in Arm 3, 
an active control arm, will be offered the common option 
and three predicted ‘less preferred’ options. The primary 
outcome will be uptake of HIV testing.
Ethics and dissemination Ethical approval was obtained 
from the Duke University Health System IRB, the University 
of South Carolina IRB, the Ethics Review Committee at 
Kilimanjaro Christian Medical University College, Tanzania’s 
National Institute for Medical Research, and the Tanzania 
Food & Drugs Authority (now Tanzania Medicines & 
Medical Devices Authority). Findings will be published 
Strengths and limitations of this study
 ► The pragmatic randomised controlled trial de-
scribed in this protocol paper includes males 
and females at high risk of HIV infection; the im-
plementation of the trial in collaboration with all 
HIV testing providers in the study area allows for 
the evaluation of testing uptake in a nearly closed 
system.
 ► The study goes beyond the traditional approach 
of evaluating single- offer (‘one- size- fits- all’) in-
terventions by identifying combinations of testing 
options that explicitly target preference heteroge-
neity in the target population.
 ► The methods used to identify the intervention con-
ditions evaluated in the trial, including the latent 
class analysis of data from the discrete choice ex-
periment (DCE) used to elicit heterogeneous popu-
lation preferences for HIV testing, may be applied 
to other contexts and may lead to the development 
of new implementation science approaches for 
systematically adapting effective interventions to 
local contexts.
 ► The study design will allow for separate esti-
mates of the effects of short messaging system 
(SMS) reminders, the issuance of HIV testing in-
vitation cards, the heterogeneity- focused test-
ing offer, and an incentive offer on HIV testing 
rates.
 ► Potential limitations include loss to follow- up 
during the multiphase study, the finite range of 
HIV testing characteristics that can be included 
in a DCE, ordering effects and exogenous events 
during the study period that may influence rates of 
HIV testing across study arms, and limited gener-
alisability of specific study findings to other popu-
lations and settings.
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in peer- reviewed journals. The use of rigorous DCE methods for the 
preference- based design and tailoring of interventions could lead to novel 
policy options and implementation science approaches.
Trial registration number NCT02714140.
BACKGROUND
In 2018, 37.9 million people were living with HIV world-
wide, and 770 000 died of HIV- related illnesses.1 HIV 
counselling and testing (HCT) is a cost- effective interven-
tion for increasing HIV serostatus awareness,2 3 a point 
of entry into HIV care and treatment, and an important 
means of primary and secondary HIV prevention.4 HIV 
Prevention Trials Network Protocol 052 conclusively 
demonstrated a marked reduction in HIV transmission 
among serodiscordant couples in which the HIV- infected 
partner was begun on antiretroviral therapy early in the 
course of infection.5 Subsequently, public health officials 
and policymakers, considering treatment as prevention, 
have called for dramatic increases in HIV testing—as 
frequently as annually in many populations and semian-
nually among individuals at high risk.6
In 2014, the Joint United Nations Programme on HIV/
AIDS (UNAIDS) set for 2020 the ambitious 90-90-90 
target: diagnosing 90% of all persons living with HIV 
(PLWH), initiating treatment for 90% of those diagnosed, 
and achieving viral suppression for 90% of those treated.7 
While substantial progress has been made towards these 
targets since 2014, most countries remain short of at least 
one target, and the number of undiagnosed HIV infec-
tions in every region are considered a major hindrance to 
achieving the UNAIDS targets and ending the epidemic.8 
Novel approaches are needed to increase testing uptake, 
especially among high- risk groups.
In order to establish the diagnosis of HIV in 90% of 
all PLWH in Eastern and Southern Africa, more than 
1 million undiagnosed infected persons need to test, 
including 190 000 in Tanzania.4 6 9 Tanzania’s 2017–2022 
Health Sector HIV and AIDS Strategic Plan (HSHSP- IV) 
lists as a key challenge that HIV testing services ‘need to be 
more efficient and ambitious to meet the 90-90-90 targets 
through more targeted testing approaches.’10 Evalua-
tions of population preferences for testing have typically 
focused on the acceptability of specific testing options, 
such as home- based,11–13 provider- initiated,14–17 or work-
place testing,18 19 usually without consideration or offer 
of other options. Results from these narrow assessments 
do not probe the potential diversity in testing preferences 
among target populations and cannot characterise which 
testing options will maximise uptake of testing.20–22
Discrete choice experiments (DCEs), grounded in the 
economic theory of utility maximisation, are specifically 
designed to provide information about individuals’ pref-
erences for varying characteristics of multiattribute prod-
ucts. The DCE method is based on the assumption that a 
product or service such as HCT can be described in terms 
of its characteristics, namely attributes and levels within 
attributes. Participants are repeatedly asked to choose 
between two or more alternatives in choice scenarios 
simulating real choice decisions. Each alternative differs 
in the arrangement of attribute levels presented to the 
participant. The choice scenarios are systematically varied 
by means of an experimental design.23–26 Relative attri-
bute importance, the utility that respondents derive from 
the diverse options, and trade- offs, that is, the willing-
ness to trade between attribute levels, can be quantified 
analytically.27 DCEs are used increasingly to understand 
patient perspectives and to design patient- centred inter-
ventions. Although DCEs have been used in various 
contexts related to HIV, including testing,20 28–32 preven-
tion,33–36 service delivery,37–39 and treatment,40–44 to our 
knowledge, DCEs have not yet been used to systematically 
design HCT interventions.
Below, we describe the study protocol for a pragmatic 
randomised controlled trial (PRCT) that evaluates the 
efficacy of a targeted, preference- informed HCT offer for 
improving rates of HIV testing in high- risk populations. 
The testing offer is developed using data from a DCE and 
designed to match the heterogeneous HIV testing pref-
erences in the target population. To our knowledge, this 
is the first PRCT in which the study conditions are opti-
mised using data from a DCE, and the first PRCT that 
evaluates an intervention explicitly targeting preference 
heterogeneity.
METHODS AND ANALYSIS
Study aim and hypothesis
The aim of this study is to evaluate the efficacy of a 
preference- informed, heterogeneity- focused HCT offer 
for improving rates of HIV testing among two high- risk 
populations. We hypothesise that an HCT offer matched 
to the specific preferences of the intended target popu-
lation and explicitly accounting for preference hetero-
geneity within these populations will increase rates of 
testing relative to a control offer.
Study setting
The study is conducted in Moshi, Tanzania. Moshi is the 
commercial centre and administrative capital of the Kili-
manjaro Region in Northern Tanzania and has an esti-
mated population of about 200 000.45 Moshi has 25 HCT 
facilities, including 8 care and treatment centres (CTCs), 
which provide free HIV care to PLWH.46 The study is 
implemented with support from the Regional Medical 
Officer and the Regional AIDS Control Coordinator of 
the Kilimanjaro Region.
Study participants
The study population comprises women employed in bars, 
restaurants, and guesthouses serving alcohol to patrons 
(‘female barworkers’, FBW) and male mountain porters 
who are supporting climbers of nearby Mount Kiliman-
jaro (‘Kilimanjaro mountain porters’, KMP). The Regional 
AIDS Control Coordinator identified these groups as popu-
lations at high risk of HIV infection who could benefit from 
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increased rates of testing; we subsequently showed that FBW 
and KMP engage in higher rates of HIV risk behaviours than 
randomly selected male and female community members in 
the same setting.20 For example, compared with randomly 
selected community members, FBW and KMP reported 2–3 
times as many lifetime sexual partners, higher rates of sexu-
ally transmitted illnesses, and higher rates of having sex in 
exchange for money or gifts, but similar numbers of life-
time HIV tests.20 A census of bars and female barworkers, 
conducted by the study team between February and June 
of 2016, identified 612 venues within Moshi, with 2 059 age- 
eligible FBW. There are an estimated 10 000 KMP in the 
Kilimanjaro Region.47 48
Inclusion criteria
Eligible study participants are ages 18 or older, reside 
in Moshi, are able to read, and have no concrete plans 
to leave the study area during the 12–15- month period 
following study enrolment.
Outcome measure
The study outcome of interest is uptake of HIV testing. 
During the multiphase study (see below), the outcome 
is ascertained repeatedly by counsellors’ documenta-
tion of participants’ HIV tests, self- reports from study 
participants, or both. In the PRCT and one preceding 
study phase, coded HIV testing invitation cards will be 
distributed to participants and HIV tests will be tracked 
on the basis of cards returned to any HIV testing centre 
in the study area. Self- reports capture tests outside the 
study area and tests without cards. The primary outcome 
measure is counsellor- documented uptake of testing. A 
secondary outcome measure is counsellor- documented 
or self- reported uptake of testing.
STUDY DESIGN
The study is comprised of five sequential phases (figure 1). 
The target duration for each phase is 13 weeks (91 days).
Phase A: reference phase
Phase A includes no intervention. The purpose of this 
phase is to inform estimates of background rates of HIV 
testing among individuals participating in a research study 
focusing on HIV testing. A phone survey after 13 weeks (91 
days) will ask participants about any HIV test during Phase 
A.
Phase B: SMS phase
In Phase B, a short messaging system (SMS) reminder 
message to test for HIV will be sent to participants 4 weeks 
(28 days) after the beginning of Phase B. The purpose of 
this phase is to inform estimates of the effect of an SMS 
reminder on rates of HIV testing. A phone survey after 13 
weeks (91 days) will ask participants about any HIV test 
during Phase B.
Phase C: invitation phase
In Phase C, participants will be given a credit card- sized 
invitation card describing an HIV testing option that 
combines features commonly available in the study area, 
and that, on average, are most preferred among study 
participants (‘common option’). Four weeks (28 days) 
after the beginning of Phase C, participants will be sent 
an SMS reminder to test for HIV as shown on the invita-
tion card given to them. The purpose of this study phase 
is to inform estimates of the effect of a testing invitation 
on rates of HIV testing. A phone survey after 13 weeks 
(91 days) will ask participants about any HIV test during 
Phase C.
Phase D: the pragmatic randomised controlled trial
Phase D is a PRCT that includes three parallel study arms 
(table 1). All participants will receive an HIV testing offer 
comprised of four invitation cards describing preference- 
informed HIV testing options. Participants will be asked 
to test for HIV using their individually most preferred 
of the four testing options given to them. Options will 
be identified using mixed logit and latent class analyses 
of data from a DCE with members of the target popula-
tions (see below). Arm 1 participants will be offered the 
common option and three ‘targeted’ options, predicted 
to be jointly more preferred than the common option 
and comprising testing features widely available in the 
study area. Arm 2 participants will be offered the common 
option and three ‘enhanced’ options, which are also 
Figure 1 Study design. SMS, short messaging system.
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predicted to be jointly more preferred than the common 
option but include additional features that are not yet 
widely available in the study area. Arm 3 participants 
will be offered the common option and three options 
that are jointly predicted to be ‘less preferred’ than the 
common option. In other words, for arm 3 participants, 
the common option is the predicted most preferred of 
the four options; the other three options, on average, 
provide no additional value. Arms 1 and 2 are interven-
tion arms. Arm 3 represents an active control arm: study 
involvement in Arm 3 is the same as in Arms 1 and 2. Four 
weeks (28 days) after the beginning of Phase D, partici-
pants will be sent an SMS reminder to test for HIV using 
any of the testing options given to them. The purpose of 
this study phase is to obtain estimates of the effect of a 
heterogeneity- focused HIV testing offer on rates of HIV 
testing. A phone survey after 13 weeks (91 days) will ask 
participants about any HIV test during Phase D.
Phase E: incentive phase
In phase E, participants will be offered an incentive to test 
for HIV using their choice of any of the testing options 
remaining to them from Phase D. An SMS reminder will 
be sent to participants 4 weeks (28 days) after the begin-
ning of Phase E. The purpose of this phase is to inform 
estimates of the effect of a conditional financial transfer 
(CFT) offer on testing decisions and identify the most 
preferred testing option among those offered, among 
participants who did not test during Phase D.
The study design will allow for separate estimates of the 
effects on HIV testing rates of:
 ► an SMS reminder message,
 ► a testing invitation,
 ► a heterogeneity- focused testing offer, and
 ► a CFT offer.
Assignment to study arms
Participant IDs will be randomly assigned to study arms 
using a random number generator. The testing offer in 
Phase D will reflect the study arm assigned to the respec-
tive Participant ID. The random assignment is expected 
to result in approximately equal numbers of participants 
in each study arm.
Design of the intervention
Overview
A DCE will be used to elicit information on the distribu-
tion of preferences for feasible and modifiable character-
istics of HIV testing options in the target population. DCE 
data will be analysed, and results of these analyses will be 
used to identify four types of testing options that will be 
offered to participants in the PRCT:
 ► A ‘common’ option. This single testing option 
combines testing features that are widely available in 
the study area, and, on average, are most preferred 
among study participants. This option will be offered 
to all participants in Phases C and D.
 ► Three ‘targeted’ options. This set of testing options, 
comprising features widely available in the study 
area, is predicted to be jointly more preferred than 
the common option by the largest possible share of 
participants.
 ► Three ‘enhanced’ options. Enhanced testing options 
include additional features that are not yet widely 
available in the study area (eg, oral testing). The set 
of enhanced testing options is predicted to be jointly 
more preferred than the common option by the 
largest possible share of participants.
 ► Three ‘less preferred’ options. This set of testing 
options includes options that are predicted to be 
equally or less preferred than the common option by 
the largest possible share of participants.
The design decision to offer three targeted, enhanced, 
and less preferred options was driven by practical consid-
erations: (1) a choice from four alternatives (the common 
option plus three options specific to the study arm) is 
expected to be cognitively feasible for participants, (2) 
Table 1 HIV testing options offered across the three study arms in the pragmatic randomised controlled trial
Arm Offers Description
1 One common 
option
Combines the on average most preferred levels of each attribute included in the DCE, as described by 
the mean parameter estimates from a mixed logit model.
Three targeted 
options
Comprise features widely available in the study area. The targeted options are predicted to be jointly 
more- preferred than the common option by the largest possible share of participants.
2 One common 
option
Combines the on average most preferred levels of each attribute included in the DCE, as described by 
the mean parameter estimates from a mixed logit model.
Three enhanced 
options
Includes additional features that are not yet widely available in the study area. The enhanced options 
are predicted to be jointly more- preferred than the common option by the largest possible share of 
participants.
3 One common 
option
Combines the on average most preferred levels of each attribute included in the DCE, as described by 
the mean parameter estimates from a mixed logit model.
Three less 
preferred options
Includes options that are widely available in the study area and jointly predicted to be equally or less- 
preferred than the common option by the largest possible share of participants.
DCE, discrete choice experiment.
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the implementation of 10 testing options (one common 
option, plus three targeted, three enhanced and three 
less preferred options) as part of this study is feasible 
from a logistical and budgetary perspective, and (3) the 
widespread implementation of three testing options that 
target preference heterogeneity is feasible in the study 
area. The statistical analysis of the DCE data (see below) 
will determine whether the testing offers differ between 
FBW and KMP.
Development and fielding of the DCE
A DCE with 300 FBW and 300 KMP recruited prior to 
the PRCT will characterise the patterns and variability 
in HIV testing preferences in the target population. The 
DCE development will follow guidelines and procedures 
established in our prior studies of HIV testing prefer-
ences.21 23 49 Focus group discussions with members of the 
target populations will be used to prioritise HIV testing 
features with respect to their expected influence on HIV 
testing decisions and to establish levels of features that 
represent plausible trade- offs in actual or hypothetical 
HIV testing interventions. Reconciling prior qualita-
tive work22 with the objectives of the PRCT, the DCE is 
expected to include feasible attributes and levels across 
three domains: privacy and confidentiality (eg, testing 
venue, different types of counselling), accessibility and 
value (testing availability, additional services provided) 
and perceived quality and accuracy (eg, type of sample 
for the HIV test).
In the DCE survey, respondents will be introduced to 
each attribute and level and asked to complete 12–16 
choice tasks. Each choice task will include three hypothet-
ical testing options; participants will be asked to identify 
their preferred alternative. The combination of alterna-
tives presented to respondents as part of the DCE will be 
varied according to a d- efficient statistical design,50 gener-
ated in Ngene software (ChoiceMetrics). Survey content 
and presentation will be tested in up to 40 guided indi-
vidual pretest interviews. Pilot studies with at least 200 
participants will yield statistical priors that inform the 
statistical design of the final DCE. DCE surveys will be 
administered in- person, in Kiswahili, using tablet devices, 
by trained research staff using the custom- built survey 
software, comet (Selway Labs).
Continuous recruitment and enrolment may result 
in overlap between DCE survey respondents and PRCT 
participants. All PRCT participants will complete the 
DCE survey to allow for comparisons of stated prefer-
ences (DCE survey responses) and revealed preferences 
(testing decisions).
Analysis of DCE data
The analysis of DCE data will follow established guide-
lines.23 49 To estimate mean (average) preferences in 
the study population, DCE data will be first analysed in 
Stata (StataCorp) using mixed, or random parameters, 
logit models,51 which are commonly used for analysing 
DCE data,52 but focus on average preferences. To model 
systematic variation in preferences across respondents, a 
random effects latent class logit (RELCL) model will be 
estimated in Latent Gold Choice V.5.0 (Statistical Innova-
tions 2018). RELCL models allow for the joint modelling 
of systematic variation in preferences (latent classes) and 
random variation in preferences (random effects) across 
respondents.53 The Bayesian Information Criterion will 
be used to identify which model yields the best fit for the 
data.
To evaluate whether the distribution of preferences 
differs significantly between the two groups of partic-
ipants (FBW versus KMP), participant type will be 
included in the model as a covariate. If the distributions 
of preferences differ significantly across groups, sepa-
rate preference- informed testing options may need to be 
identified for FBW and KMP. On the other hand, if the 
preference distributions are broadly similar, the testing 
offer can be optimised for the joint preferences of both 
populations.
Selection of testing options for inclusion in the PRCT
Results from the mixed logit model will be used to iden-
tify the common option; results from the best- fitting 
latent class model will be used to identify the combina-
tions of targeted, enhanced and less- preferred options to 
be in included in the PRCT.
Common option
The common option will combine the most preferred 
(on average) levels of each attribute included in the DCE, 
as described by the mean parameter estimates from the 
mixed logit model.
Targeted, enhanced and less-preferred options
The latent class analysis will identify statistical group-
ings of individuals with similar sets of preferences; these 
groupings are referred to as classes. Using parameter esti-
mates from the latent class model, we will predict class- 
specific relative preferences for all feasible combinations 
of feature levels (ie, testing options), which, in turn, will 
be converted into predicted choice probabilities in a 
simulated choice between the respective testing option 
and the ‘common option’. Class- specific predicted choice 
probabilities will be aggregated across classes (taking 
into consideration the estimated class sizes) to calculate 
the share of the population predicted to prefer each 
testing option over the common option. These shares 
are used, as follows, to generate population- based rank-
ings of all feasible combinations of three testing options. 
For targeted options, we will select from all options that 
combine features currently available in the study area the 
three options that jointly maximise the share of partic-
ipants predicted to choose at least one of those three 
targeted options over the common option. Similarly, for 
enhanced options, we will select from all options that 
include additional features not yet widely available in the 
study area the three options that jointly maximise the 
share of participants predicted to choose at least one of 
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those three enhanced options over the common option. 
For less preferred options, we will select the three options 
that jointly maximise the share of participants predicted 
to prefer the common option over all less preferred 
options.
Presentation of testing options to study participants
Testing options will be presented to participants on invita-
tion cards. Each participant will be given four cards; each 
card will describe the characteristics of the testing option 
in a format similar to that presented in the DCE. The 
combination of cards given to a participant will be deter-
mined by the study arm assigned to the participant; refer-
ences to specific testing venues may be varied according 
to participants’ location of residence or preferred testing 
venue. Cards will have unique codes that allow for the 
tracking of participants’ testing uptake across testing 
venues in the study area.
SMS delivery
SMS messages will be sent via a highly versatile, low- cost, 
mHealth system, called mobile phone based appoint-
ment reminder and incentive system (mParis), which 
can autonomously send large numbers of SMS messages 
according to prespecified algorithms and is based in the 
study area.54 55
Testing incentive
During Phase E, an incentive in the amount of TSH 5000 
(~US$2.20) will be given in cash to participants presenting 
for testing with a coded testing invitation card at any of 
the testing venues in the study area. The amount is based 
on a willingness- to- accept study previously conducted in 
the same area.56
Sample size
The target sample size for the PRCT is 1200 participants, 
comprising equal numbers of FBW and KMP. Randomi-
sation across study arms is expected to result in three 
groups with approximately 400 participants each.
Recruitment
Participants for formative work will be recruited using 
convenience and snowball sampling. For DCE surveys and 
the PRCT, the goal is to employ a systematic recruitment 
approach that minimises biases. Mountain porters will be 
recruited from the Mweka gate of Kilimanjaro National 
Park. The Mweka gate is selected because of its proximity 
to Moshi (~15 km); four of six popular climbing routes 
descend through this gate. Porters exiting the gate will 
be approached sequentially, and eligible porters will be 
handed an invitation card containing contact informa-
tion and an invitation to the study’s research office for 
consent and enrolment. For the recruitment of female 
barworkers, bars will be randomised and visited in the 
order of randomisation. Eligible FBW will be consented 
at their place of work or given invitation cards containing 
contact information and an invitation to the study’s 
research office for consent and enrolment. Recruited 
participants may receive reminder phone calls or SMS 
messages to come to the study offices for more informa-
tion and study enrolment.
Enrolment and informed consent
Eligible individuals contacted for participation in the 
study will be informed by trained study personnel of the 
study purpose, procedures, risks, and benefits during the 
informed consent process. Only consenting individuals 
will be included in the study. Study participants’ mobile 
phone numbers and the name and phone number of a 
contact person through whom they can be reached will 
be recorded to allow for phone- based follow- up.
Enrolment into the trial will be conducted in three 
sequential stages. Approximately half the participants 
will be enrolled into Phase A and one quarter each into 
Phases C and D. This approach ensures variation in the 
exposure to pre- PRCT intervention components across 
participants, thereby allowing for the estimation of 
potential ordering effects as participants move through 
the different study phases. The staggered enrolment also 
ensures a better alignment of study timelines for Phases D 
and E across participants.
Blinding
Participants will be blinded with respect to their assign-
ment across the three study arms. While research staff are 
not blinded to participants’ study arm assignment, study 
procedures are the same for all arms except for the char-
acteristics of the testing offer.
Study activities
Study activities and their schedule are shown in table 2.
Participants providing informed consent will be 
enrolled in the study. At the time of enrolment, a base-
line survey will be conducted with all participants to assess 
sociodemographic characteristics, testing history, testing 
preferences, HIV serostatus, and HIV risk.
After enrolment, participants will progress through 
up to five study phases. Phase A represents a no- inter-
vention phase. Phase B starts with the completion of the 
Phase A follow- up survey. Phase C starts with the distri-
bution of an invitation card that describes the ‘common’ 
option. Phase D starts with the distribution of four invi-
tation cards that describe the preference- informed HIV 
testing options, namely the ‘common’ option and three 
‘targeted’, ‘enhanced’, or predicted ‘less preferred’ 
options, depending on the study arm. Phase E starts with 
a phone call or SMS message offering a financial incentive 
to test. SMS reminder messages will be sent 28 days after 
the beginning of Phases B, C, D and E. Phases A and B 
will end with a short phone- based survey with study partic-
ipants. Phases C, D and E will end with a phone- based 
survey or the collection of a testing invitation card from 
testing sites, whichever occurs earlier. After the comple-
tion of Phases B and C, participants will be contacted by 
phone and SMS and invited to come to the local study 
office for follow- up.
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HIV testing will be done in accordance with Tanzania’s 
National AIDS Control Program (NACP) guidelines.57 
Since 2013, Tanzania’s National Comprehensive Guide-
lines for HIV Testing and Counselling describe specific 
retesting intervals ranging from 4 weeks to 6 months for 
most persons at elevated risk of HIV infection.58 Our own 
survey of HIV testing sites in the study area revealed that 
most counsellors continue to recommend retesting after 
3 months for all clients testing negative for HIV, regard-
less of risk. As per NACP guidelines, participants testing 
positive for HIV will be linked to care at a local CTC. 
Participants who report having tested positive for HIV, or 
those for whom documentation of a positive HIV test is 
collected from testing sites, will discontinue participation 
in HIV testing related components of the study.
Study timeline
The schedule of activities implies a minimum time of 
15 months for participants to progress through all five 
study phases. Delays in reaching participants by phone 
and delays in participants returning to study offices will 
extend the duration of follow- up. In order to minimise 
loss to follow- up prior to the PRCT and reduce variability 
in the timing of the PRCT across participants, all partici-
pants in Phases A, B or C who are 91 or more days late for 
a follow- up assessment will transition to Phase D during 
their next in- person visit. Additionally, participants may 
be directly enrolled into Phases C and D (figure 1). 
Study enrolment will continue until the target number 
of n=1200 participants in the PRCT (Phase D) has been 
reached. Follow- up will continue until 6 months after the 
last participant enters Phase D.
Participant retention
To maximise retention, study participants due for 
follow- up may receive multiple phone calls and SMS 
reminders to come to the study offices. Escalating incen-
tives, that is, incentive amounts that increase across 
consecutive study phases, will be used. The effect of selec-
tive attrition on estimates will be evaluated in sensitivity 
analyses (see below).
Statistical analysis
The primary analysis involves the comparison of testing 
rates between study arms in Phase D. The effect of the 
intervention—a preference- informed, heterogeneity- 
focused, HIV testing offer—will be described by differ-
ences in testing uptake between those offered targeted 
or enhanced options, relative to those offered predicted 
less preferred options. Statistical significance will be 
evaluated in a bivariate analysis using a χ2 test. Logistic 
regression analysis will evaluate the statistical significance 
of differences in a multivariate framework. Uptake of HIV 
testing within 3 months of the beginning of Phase D will 
be the binary outcome variable; study arm will be the key 
explanatory variable. Systematic variation in the efficacy 
of the intervention, for example, by gender or with HIV 
risk, can be modelled using interactions between study 
arm and the respective covariates.
Table 2 Schedule of activities
Phase Time point Target timing Key activity Key information collected
A tA Enrolment Baseline survey HIV testing preferences, history, HIV 
risk, sociodemographics
tAfu = tB* tA + 91 days Phone- based FU HIV testing uptake since tA
B tBs tB + 28 days SMS reminder
tBfu tB + 91 days Phone- based FU HIV testing uptake since tB
C† tBx = tC tBfu + <91 days Testing invitation (‘common’ option)
tCs tC + 28 days SMS reminder
tCfu tC + 91 days Card collection from testing sites, phone- 
based FU
HIV testing uptake since tC
D† tCx = tD tCfu + <91 days Four testing invitations, study arm specific
tDs tD + 28 days SMS reminder
tDfu tD + 91 days Card collection from testing sites, phone- 
based FU
HIV testing uptake since tD
E tE tDfu + <91 days Phone call and SMS message with 
incentive offer
tEs tE + 28 days SMS reminder
tEfu tE + 91 days Card collection from testing sites, phone- 
based FU
Choice among testing options 
offered, HIV testing uptake since tE
*The phone- based follow- up at the end of Phase A constitutes the beginning of Phase B.
†To reduce variability across participants in the timing of Phase D, some participants will be enrolled directly into Phases C and D.
FU, follow- up; SMS, short messaging system.
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Survival models with up to five observations per partic-
ipant (one each for Phases A, B, C, D and E) will be used 
to estimate the differential effects of study arm assign-
ment, SMS reminders, invitations, and conditional finan-
cial incentives, on rates of HIV testing. The time until an 
HIV test following the beginning of the respective study 
phase constitutes the dependent variable. ‘Exposure’ to 
SMS reminders, invitations, and a financial incentive are 
hypothesised to increase the ‘hazard’ of testing relative to 
no intervention. To control for potential ordering effects, 
participants exposure to intervention components in 
prior study phases (Phase B and C SMS reminders, Phase 




Statistical power in DCEs varies with sample size, the 
number of choice tasks, the number of alternatives per 
task and the number of attributes and levels, among other 
characteristics. An empirical power- test formula by Yang 
et al59 suggests that the DCE sample size (n=600) allows 
us to estimate the utility difference between the most 
and least- preferred testing options with a precision that 
is better than that of ‘the average’ DCE study. A sample 
size guidance by Orme60 suggests that the two study popu-
lations (n=300 each) are sufficiently large to derive inde-
pendent estimates for each sub- cohort.
PRCT
The sample size for the three- arm trial (n=1200) was 
selected to ensure adequate statistical power to identify 
the statistical significance of policy- relevant differences 
in testing uptake between study arms. We expect testing 
rates in Arm 3 to range from 25% among porters (as in 
our preliminary data) to 40% among barworkers (lower 
than the 59% in our preliminary data where barworkers 
were enrolled at a health facility).20 Assuming an equal 
split between study arms, 400 participants per arm yield 
65%–72% power to detect a difference of 10 percentage 
points, 94%–96% power for a difference of 15 points 
and >99% power for difference of 20 percentage points 
between the targeted, respectively enhanced, arms and 
the comparison arm (alpha=0.05, two- sided).
Reporting of results
Methods and results will be reported in accordance with 
the CONSORT reporting guidelines and its extensions 
for pragmatic randomised controlled trials (see online 
supplemental files 1–4).61
Sensitivity analyses
Extensive sensitivity analyses will describe the sensitivity of 
our estimates to the definition of the outcome variable, 
model specification and selective attrition. Estimates 
from the analysis of the secondary outcome measure 
(counsellor- documented or self- reported testing uptake) 
will be presented alongside the analysis of the primary 
outcome measure (counsellor- documented HIV testing). 
The DCE choice data will be analysed using a broad 
range of models in order to describe the sensitivity of the 
selected PRCT testing offers to model specification and 
assumptions. The effect of attrition will be estimated by 
modelling attrition as a function of observable character-
istics at the time of enrolment and weighing individual- 
level predictions of the intervention effect by the inverse 
probability of attrition. Differences between the average 
intervention effect and the attrition- weighted average 
effect will characterise the effects of selective attrition on 
our estimates.
Data security and confidentiality
A research data security plan will ensure that data are 
kept in compliance with relevant privacy regulations, 
including HIPAA; access to identifying information will 
be strictly limited. Study personnel will be instructed to 
keep the identity of all research subjects confidential and 
will sign confidentiality agreements.
Monitoring and quality assurance
Adherence to intervention protocols and the complete-
ness and quality of study data will be monitored by the 
principal investigators and a study monitor. Electronic 
data capture on tablet devices and daily uploads to secure 
servers allow for the continuous monitoring of study 
activities in near real time. All paper documents will be 
scanned. Rigorous quality assurance/quality control 
procedures will be established, including interviewer 
observation, validation and range checks during data 
entry, verification of entered data and the monitoring of 
time stamps for DCE choice tasks.
Patient and public involvement
Focus group discussions with members of the target 
populations will be used to prioritise HIV testing features 
with respect to their expected influence on HIV testing 
decisions and to establish levels of features that represent 
plausible trade- offs in actual or hypothetical HIV testing 
interventions. The results will inform the development of 
the DCE and the testing options in the PRCT.
Ethics and dissemination
The protocol was registered in  ClinicalTrials. gov 
(Protocol NCT02714140) on 21 March 2016. The 
protocol was approved by the Institutional Review 
Boards at Duke University (Duke University Health 
System IRB, Protocol Pro00075996) and the University 
of South Carolina (University of South Carolina IRB, 
facilitated review, Pro00060760) in the USA as well as 
the Ethics Review Committee at Kilimanjaro Christian 
Medical University College (Protocol #901), the National 
Institute for Medical Research (NIMR/HQ/R.8a/Vol. 
IX/2603) and the Tanzania Food & Drugs Authority 
(now Tanzania Medicines and Medical Devices Authority, 
Authorization No. TZ18CT0017). Protocol amendments 
will be submitted to these entities as required. Findings 
will be published in peer- reviewed journals. The use of 
rigorous DCE methods for the preference- based design 
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and tailoring of interventions could lead to novel policy 
options and implementation science approaches.
DISCUSSION
This study will evaluate whether an HIV testing interven-
tion, which is uniquely designed using data from a DCE and 
explicitly targets preference heterogeneity, will improve 
testing uptake. If testing rates differ between study arms, 
the results will support our hypothesis that DCE- derived 
preference data can be used to systematically design HIV 
testing interventions that target heterogeneous preferences 
among and within high- risk populations and that offering 
such interventions will increase testing uptake in target 
populations. With novel approaches to testing urgently 
needed to reach the 90-90-90 targets, the DCE and targeted 
methods used in this study may be broadly used to develop 
cost- effective testing offers that match the preferences of 
high- risk populations across diverse settings.
To our knowledge, this is the first PRCT in which the inter-
vention conditions are designed using data from a DCE, 
and the first PRCT that evaluates an intervention explic-
itly targeting preference heterogeneity. If successful, the 
methods used to understand how different groups of users 
value key characteristics of a health intervention can readily 
be applied to other settings in which interventions are 
being developed or adapted to optimise their efficacy. This 
work may demonstrate the utility of DCEs as a tool in imple-
mentation research to replace the costly practice of itera-
tively evaluating narrowly focused interventions. Thus, even 
as we apply this approach to the specific area of HIV testing, 
the study has potential to significantly advance the fields 
of patient- oriented research and implementation science. 
The methods could be used to develop new approaches to 
adapt effective interventions to local contexts, by informing 
a priori which interventions should be rolled out, and with 
which modifications, in order to maximise uptake across 
different populations and subpopulations.
Our study design and implementation approach have 
several unique components. First, the implementation of 
the study, in collaboration with all HCT providers in the 
study area, allows for the evaluation of testing uptake in 
a nearly closed system. Second, the use of an automated 
mHealth system to send large numbers of SMS messages 
according to prespecified algorithms reduces both error 
potential and cost. Third, the similarity between hypo-
thetical choice scenarios presented in the DCE and actual 
HIV testing options given to participants allows for explicit 
comparisons between stated and revealed preferences. 
Fourth, the study design allows for separate estimates of the 
effects of reminder SMS, the issuance of HIV testing invi-
tation cards and an incentive offer, on HIV testing rates. 
Finally, the approach for identifying the targeted, enhanced 
and less- preferred options is not contingent on the use of 
RELCL analysis and proprietary software; instead, it can be 
approximated using open source alternatives for example, 
in R. In a sensitivity analysis, we will evaluate the effect of 
specific model assumptions on the selection of testing 
options for the PRCT.
The study is subject to several limitations. First, feasi-
bility considerations limit the study area to include only 
HCT facilities in Moshi municipality. While coded invita-
tion cards collected from all HCT providers offer defini-
tive evidence of a completed HIV test, participants may 
test without invitation cards and may test outside the study 
area. Sensitivity analyses will characterise the effect of 
using only provider- documented testing uptake (primary 
outcome) versus provider- documented or self- reported 
testing uptake (secondary outcome) on estimates.
Second, the preference estimates from the DCE, pref-
erence informed testing options, and estimated effect 
sizes are not generalisable to other high- risk groups in 
Tanzania or other parts of Africa. However, if this study 
is successful, it will support the broader use of stated 
preference methods to systematically elicit the prefer-
ences of key populations and facilitate corresponding 
adaptations to HIV testing options. We acknowledge that 
study eligibility criteria include literacy, and study proce-
dures involve phone- based and SMS- based contact with 
participants. While literacy in the region was 96% in 2012 
and, in 2017, 93% of urban households had a mobile 
phone62 63 the exclusion of illiterate persons and limited 
mobile phone access may influence the results. It is also 
possible that individuals who are likely to move (and thus 
may not be enrolled or are lost to follow- up) may have 
different preferences and opportunities for HIV testing.
Third, participants’ progression through multiple study 
phases may influence testing uptake in the PRCT. Ideally, all 
tangential intervention components (SMS reminders, invi-
tation cards, incentives) could be evaluated alongside the 
preference- informed HIV testing offer as part of a multiarm 
RCT; however, the sample size required for such a trial is not 
feasible. A multistage enrolment approach and the inclu-
sion of variables describing participants’ exposure to SMS 
reminders, testing offers and HIV tests in prior study phases 
as covariates allow us to estimate the direction and magni-
tude of such ordering effects on uptake. In our study, we 
will not be able to estimate an unconditional effect of incen-
tives on HIV testing uptake, as concurrent incentivised and 
non- incentivised testing offers were not considered viable 
among potentially closely knit community members (eg, 
barworkers in the same bar, porters climbing together).
Finally, DCE surveys contain a limited set of testing 
characteristics; the finite range of attributes and levels is 
a limitation of DCEs in general. Preference- relevant and 
choice- relevant testing characteristics may differ in other 
settings, and changes in the testing environment and avail-
able testing options may occur during the study period. 
While adaptations to the preference survey and analysis of 
DCE data may be necessary and require technical expertise, 
such costs are expected to be far smaller than costs associ-
ated with large- scale, iterative trials of potentially ineffective 
HCT testing interventions.
In conclusion, this study evaluates the critical link between 
preference- based intervention design and efficacy. If the 
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PRCT indicates that a preference- informed, heterogeneity- 
focused HCT offer increases testing rates, the testing 
options evaluated in this study can be offered to high- risk 
populations in the study area, and the preference elicita-
tion method and tools can be used to inform the design of 
testing options that better match the preferences of other 
high- risk populations, both locally and in other settings.
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